Renal Denervation for Arrhythmias: Hope or Hype?
- 363 Downloads
Renal artery denervation (RDN) has been introduced as an ablation procedure that can effectively treat drug-resistant forms of hypertension. The ablative lesions reduce the afferent and efferent sympathetic nerve traffic to and from the kidneys, thus improving blood pressure control. Because of better control of blood pressure, and because the procedure reduces central sympathetic output to sensitive structures within the cardiovascular system, it has been hypothesized that RDN may be a valuable antiarrhythmic intervention. Preliminary results using RDN for atrial fibrillation control are promising. This review focuses on the mechanisms by which RDN may function as an antiarrhythmic treatment and early clinical results.
KeywordsRenal artery denervation Antiarrhythmia Atrial fibrillation Ventricular tachycardia Arrhythmias
Compliance with Ethics Guidelines
Conflict of Interest
Jonathan S. Steinberg has been a consultant for and has received grant support from Medtronic, St. Jude Medial, and Biosense-Webster.
Evgeny Pokushalov declares that he has no conflict of interest.
Suneet Mittal declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 21.Zhao Q, Yu S, Zou M, et al. Effects of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. JICE. 2012;35:119–25.Google Scholar
- 26.•• Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–70. This is the first study, performed as a prospective randomized trial, to demonstrate proof of principle that RDN may have clinical antiarrhythmic efficacy for AF. PubMedCrossRefGoogle Scholar